



VERSION WITH MARKINGS TO SHOW CHANGES MADE

8. (Amended) A method according to [any of claims 1 to 7] claim 1, wherein in said compound said anionic- or cationic-containing moiety or moieties are bonded to amine, sulfhydryl, hydroxy or other reactive terminal groups of the dendrimer by amide or thiourea linkages.

9. (Amended) A method according to [any of claims 1 to 8] claim 1, wherein in said compound said anionic- or cationic-containing moieties are selected from the group consisting of sulfonic acid-containing moieties, carboxylic acid-containing moieties (including neuraminic and sialic acid-containing moieties and modified neuraminic and sialic acid-containing moieties), boronic acid-containing moieties, phosphoric and phosphonic acid-containing moieties (including esterified phosphoric and phosphonic acid-containing moieties), primary, secondary, tertiary or quaternary amino-containing moieties, pyridinium-containing moieties, guanidinium-containing moieties, amidinium-containing moieties, phenol-containing moieties, heterocycles possessing acidic or basic hydrogens, and zwitterionic-containing moieties.

10. (Amended) A method according to [any of claims 1 to 9] claim 1, wherein in said compound the moiety or moieties which are bonded to amino or other reactive terminal groups of the dendrimer are selected from the following groups, in which n is zero or a positive integer:
































—ArXP(=O)(OR)₂ X=O, CH₂, CHF, CF₂ R=alkyl, aryl, H, Na.

—ArXP(=O)(OR¹)(NR²R³) X=O, CH₂, CHF, CF₂ R¹=alkyl, aryl, H, Na R², R³=alkyl, aryl


—Ar[P(=O)(OR)₂]_n R=alkyl, aryl, H, Na n=1-3

—Ar[B(OH)₂]_n n=1-3


—Ar[COOH]_n n=1-3



09786972-051101



R = alkyl or arylalkyl; R₁, R₂, R₃ (which may be same or different) = alkyl or arylalkyl



11. (Amended) A method according to [any one of claims 1 to 10] claim 1, wherein said compound is selected from the group consisting of:

- xlii. alkylsulfonic acid terminated dendrimers;
- xlili. sulfoacetamide terminated dendrimers;
- xliv. sulfosuccinamic acid terminated dendrimers;
- xlvi. N-(2-sulfoethyl) succinamide terminated dendrimers;
- xlvi. 4-sulfophenylthiourea terminated dendrimers;
- xlvi. 3,6-di-sulfonaphthylthiourea terminated dendrimers;
- xlvi. 4-sulfonaphthylthiourea terminated dendrimers;
- xlix. 3,5-di-sulfophenylthiourea terminated dendrimers;
- l. 3,6,8-tri-sulfonaphthylthiourea terminated dendrimers;
- li. 4-(sulfomethyl) benzamide terminated dendrimers;
- lii. 4-sulfobenzamide terminated dendrimers;
- liii. N-(4-sulfophenyl) propanamide terminated dendrimers;
- liv. 4-sulfophenylurea terminated dendrimers;
- lv. N,N,N-tri-methylglycinamide terminated dendrimers;
- lvi. 4-trimethylammonium benzamide terminated dendrimers;
- lvii. 4-(trimethylammoniummethyl)benzamide terminated dendrimers;
- lviii. N-(2-acetoxyethyl)-N,N-(dimethylammonium)methyl-carboxamide terminated dendrimers;
- lix. guanidino terminated dendrimers;
- lx. 4-([1,4,8,11-tetraazacyclotetradecane]methyl)benzamide terminated dendrimers;

- lxi. 4-carboxy-3-hydroxy-benzylamine terminated dendrimers;
- lxii. 4-carboxyphenylamide terminated dendrimers;
- lxiii. 3,5-dicarboxyphenylamide terminated dendrimers;
- lxiv. 4-phosphonooxyphenylthiourea terminated dendrimers;
- lxv. 4-(phosphonomethyl)phenylthiourea terminated dendrimers;
- lxvi. ethyl-4-(phosphonomethyl)phenylthiourea terminated dendrimers;
- lxvii. (8-octanamido)-5-acetamido-3,5-dideoxy-2-thio-D-glycero- β -D-galacto-2-nonulopyranosidoic acid terminated dendrimers;
- lxviii. (11-undecanamido)-5-acetamido-3,5-dideoxy-2-thio-D-glycero- β -D-galacto-2-nonulopyranosidoic acid terminated dendrimers;
- lxix. (acetamido)-5-acetamido-3,5-dideoxy-2-thio-D-glycero- β -D-galacto-2-nonulopyranosidoic acid terminated dendrimers;
- lxx. (4-butanamido)-5-acetamido-3,5-dideoxy-2-thio-D-glycero- β -D-galacto-2-nonulopyranosidoic acid terminated dendrimers;
- lxxi. (4-methylbenzamido)-5-acetamido-3,5-dideoxy-2-thio-D-glycero- β -D-galacto-2-nonulopyranosidoic acid terminated dendrimers;
- lxxii. (8-octanamido)-4-azido-5-acetamido-3,4,5-trideoxy-2-thio-D-glycero- β -D-galacto-2-nonulopyranosidoic acid terminated dendrimers;
- lxxiii. (8-octanamido)-4-amino-5-acetamido-3,4,5-trideoxy-2-thio-D-glycero- β -D-galacto-2-nonulopyranosidoic acid terminated dendrimers;
- lxxiv. 4-benzamidoboronic acid terminated dendrimers;
- lxxv. 3,5-dicarboxyphenylthiourea terminated dendrimers;
- lxxvi. 4-phosphonooxyphenylthiourea terminated dendrimers;
- lxxvii. 4-phosphonophenylthiourea terminated dendrimers;
- lxxviii. 4,6-diphosphononaphthylthiourea terminated dendrimers;
- lxxix. fluoresceinthiourea terminated dendrimers;
- lxxx. (phenyl-3-boronic acid)-thiourea terminated dendrimers;
- lxxxi. pyridinium dodecylcarboxamide terminated dendrimers; and
- lxxxii. saccharin terminated dendrimers.

12. (Amended) A method according to [any of claims 1 to 11] claim 1, wherein said treatment comprises inhibition of toxins and toxic peptides of biological

origin or toxins and toxic peptides released during bacterial, protozoal, fungal or viral infection.

13. (Amended) A pharmaceutical or veterinary composition for prophylactic or therapeutic inhibition of a toxic material or substance in a human or non-human animal, which comprises an anionic or cationic dendrimer as defined in [any of claims 1 to 11] claim 1, in association with at least one pharmaceutically or veterinarily acceptable carrier or diluent.

Respectfully submitted,

By Stephen A. Bent

Stephen A. Bent
Attorney for Applicant
Registration No. 29,768

Date March 13, 2001

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5404
Facsimile: (202) 672-5399